Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections. 1984

R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet

Vindesine was administered intravenously to 12 patients with advanced cancer. Treatment was repeated after 2 weeks or more with a 1.5-to 2-fold increased dose of vindesine. Five patients received one or two additional injections at the higher dose level. One patient was given 0.4, 1 and 4 mg of vindesine on days 1, 3 and 6 and then 8 mg on days 19 and 34. Plasma samples and urine were collected over 3 days after injection and monitored for vindesine by radioimmunoassay. Significant time-dependence of vindesine plasma concentration decay kinetics at a constant dose was observed in four patients out of six. The comparison of the kinetics after administration of different doses to the same patient revealed frequent deviations from linearity with no obvious general trend. Urinary excretion was very low (1-12% of the dose), and urinary excretion rates correlated with plasma concentrations. Renal clearances were variable from one patient to another and also for the same patient from one injection to another. These data were interpreted in terms of time- and dose-dependence of vindesine pharmacokinetics.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
January 1984, Cancer chemotherapy and pharmacology,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
January 1985, Cancer research,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
January 1979, Cancer chemotherapy and pharmacology,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
April 1979, British journal of clinical pharmacology,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
January 1979, British journal of clinical pharmacology,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
July 1988, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
September 1948, Lancet (London, England),
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
June 1973, Anesthesiology,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
February 1980, British journal of clinical pharmacology,
R Rahmani, and M Martin, and R Favre, and J P Cano, and J Barbet
November 2007, Paediatric anaesthesia,
Copied contents to your clipboard!